ZYBERNO
Stock Report
Updated Aug 26, 2026

PASITHEA THERAPEUTICS CORP. (KTTAW)

Healthcare • NASDAQ

$0.01

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
18.0/100
POOR BUSINESS
PASITHEA THERAPEUTICS CORP. (KTTAW) scores 18/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-49.5%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.04x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-298.8%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

PASITHEA THERAPEUTICS CORP. (KTTAW) stock report — Zyberno Score 18/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.01
Market Cap:$237.54K

Valuation Multiples (2)

P/B Ratio:0.00x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:-$43.59M

Price Action & Momentum (1)

% of 52-Week High:6.2%
B. Profitability Assessment

Return Metrics (5)

ROA:-46.8%
Reinvestment Rate:23.2%
Fundamental Growth Rate (g):-69.2%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$12.43K
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:77.8%
Latest Earnings Filed:2026-08-14
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:26.25x
Quick Ratio:26.25x
Cash Ratio:24.85x

Leverage Analysis (3)

Debt To Equity Ttm:0.04x
Debt-to-Equity Ratio:0.04x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:46,406,124.00
Cash And Cash Equivalents:45,663,782.00
Long Term Debt:$0.00
Net Debt:-$43.83M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$23.96M

Bottom Line Performance (3)

-$21.29M
Income Before Tax:-$21.29M
Ebitda Ttm:-23,923,322.00

Operating Expenses (5)

Operating Expenses:0.00
R And D Expense:10,730,531.00
Sga Expense:13,225,612.00
Income Tax Expense:$0.00
Interest Expense:0.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$51.71M
Current Assets:$48.24M
Ppe Net:113,564.00
Goodwill:1,262,911.00
Intangible Assets:$3.47M

Liability Structure (4)

Total Liabilities:1,870,258.00
Current Liabilities:1,837,917.00
Long Term Debt:$0.00
Short Term Debt:$1.84M

Equity & Capital (3)

Equity:$49.84M
Retained Earnings:-$78.15M
Common Stock:500,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:1,837,917.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:329,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$16.94M$0.00

Investment Activities (1)

Investing Cash Flow:-$1.76M

Financing Activities (3)

Financing Cash Flow:$750.00
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:2,078,348.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:32,821.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-0.92
-$0.92
Earnings Per Share Ttm:-$0.66

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$0.47

Book Value & Capital (2)

Book Value Per Share:$1.55
Cash Per Share:1.42

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:23.2%
Fundamental Growth Rate (g):-69.2%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):-11.2%
C. Company Profile & Context

Corporate Information (6)

Symbol:KTTAW
Company Name:PASITHEA THERAPEUTICS CORP.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:32.10M
Shares Outstanding Basic:32.10M
Shares Outstanding Diluted:32.10M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-26 13:35:18 UTC
Data Timestamp:2026-08-26T13:35:18.720361
Scroll to Top